SBIR/STTR Research Award
Targeting Breast Cancer Metastasis with Id1
Award amount
$1,553,329Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ORGANIX CHEMISTRY SOLUTIONS LLC
- Proposal award date
- 2017-08-01
- Contract end date
- 2019-07-31
- UEI
- HEGURQ5WJRQ9
- Solicitation number
- PA15-269
- Topic code
- 102
Research abstract
Metastasis of aggressive breast cancer is a devastating and ultimately fatal conditionThe current drugs
which are used to treat breast cancer focus on the reduction of the tumor size and have proven to be successfulHowevercurrently there are no available treatment options which can effectively inhibit tumor invasion and
metastasisNovel drug strategies therefore are needed to treat this chronicfatal and incurable conditionOur
therapeutic strategy for the treatment of aggressive breast cancer is based on reducing IdexpressionIn the
Phasesegment of this Fast Track proposal our focus will be on developing lead compounds that display a
favorable in vivo profileIn Phase II segment of this proposal our lead compounds will be evaluated in multiple
in vivo modelsWe will also develop leads that display a favorable ADME Tox profileThe ultimate goal of this
proposal is to develop a novel therapeutic approach for the treatment of metastatic human breast cancers by
down regulation of Id
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Targeting Breast Cancer Metastasis with Id1
- Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa
- Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment
- The first reversible radioligand for the hVMAT2 [3H]reserpine binding site
- Benzodiazepine Analogs as Novel Treatments for Catatonia
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
15 SBIR/STTR records share this UEI (1995–2017). Reported award amounts total $6,742,699. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services